US20050158362A1 - Polymeric, fiber matrix delivery systems for bioactive compounds - Google Patents
Polymeric, fiber matrix delivery systems for bioactive compounds Download PDFInfo
- Publication number
- US20050158362A1 US20050158362A1 US10/312,189 US31218905A US2005158362A1 US 20050158362 A1 US20050158362 A1 US 20050158362A1 US 31218905 A US31218905 A US 31218905A US 2005158362 A1 US2005158362 A1 US 2005158362A1
- Authority
- US
- United States
- Prior art keywords
- bioactive compound
- polymeric
- bioactive
- fibers
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T442/00—Fabric [woven, knitted, or nonwoven textile or cloth, etc.]
- Y10T442/20—Coated or impregnated woven, knit, or nonwoven fabric which is not [a] associated with another preformed layer or fiber layer or, [b] with respect to woven and knit, characterized, respectively, by a particular or differential weave or knit, wherein the coating or impregnation is neither a foamed material nor a free metal or alloy layer
- Y10T442/2525—Coating or impregnation functions biologically [e.g., insect repellent, antiseptic, insecticide, bactericide, etc.]
Definitions
- the present invention relates to delivery systems comprising polymeric fiber matrices, film coatings or braided/woven structures for the controlled release of bioactive compounds.
- the delivery systems of the present invention may be comprised of either biodegradable or nondegrading polymeric fibers. In one embodiment, these fibers have submicron and/or micron diameters.
- Bioactive compounds are included in the delivery system either by suspending the compound particles or dissolving the compound in the polymer solution used to produce the fibers.
- U.S. Pat. No. 3,991,766 describes a medicament repository consisting of a surgical element in the form of tubes, sheets, sponges, gauzes or prosthetic devices of polyglycolic acid having incorporated therein an effective amount of a medicament.
- U.S. Pat. No. 4,655,777 describes a method for producing a biodegradable prothesis or implant by encasing an effective amount of fibers of calcium phosphate or calcium aluminate in a matrix of polymer selected from the group consisting of polyglycolide, poly(DL-lactide), poly(L-lactide), polycaprolactone, polydioxanone, polyesteramides, copolyoxalates, polycarbonates, poly(glutamic-co-leucine) and blends, copolymers and terpolymers thereof to form a composite.
- polymer selected from the group consisting of polyglycolide, poly(DL-lactide), poly(L-lactide), polycaprolactone, polydioxanone, polyesteramides, copolyoxalates, polycarbonates, poly(glutamic-co-leucine) and blends, copolymers and terpolymers thereof to form a composite.
- U.S. Pat. No. 4,818,542 discloses a method for preparing a spherical microporous polymeric network with interconnecting channels having a drug distributed within the channels.
- U.S. Pat. No. 5,128,170 discloses a medical device and methods for manufacturing medical devices with a highly biocompatible surface wherein hydrophillic polymer is bonded onto the surface of the medical device covalently through a nitrogen atom.
- U.S. Pat. No. 5,545,409 discloses a composition and method for controlled release of water-soluble proteins comprising a surface-eroding polymer matrix and water-soluble bioactive growth factors.
- U.S. Pat. No. 5,769,830 discloses synthetic, biocompatible, biodegradable polymer fiber scaffolds for cell growth. Fibers are spaced apart by a distance of about 100 to 300 microns for diffusion and may comprise polyanhydrides, polyorthoesters, polyglycolic acid or polymethacrylate.
- the scaffolds may be coated withe materials such as agar, agarons, gelatin, gum arabic, basement membrane material, collagen type I, II, III, IV or V, fibronectin, laminin, glycosaminoglycans, and mixtures thereof.
- U.S. Pat. No. 5,898,040 discloses a polymeric article for use in drug delivery systems which comprises a polymeric substrate with a highly uniform microporous polymeric surface layer on at least part of the substrate.
- WO 93/07861 discloses polymer microspheres of 50 to 100 microns comprising a compound contained in a fixed oil within the polymer microsphere.
- U.S. Pat. No. 5,969,020 discloses a foam precursor comprising a crystalline thermoplastic polymer and solid crystalline additive for use in preparation of drug delivery systems.
- WO 99/18893 describes a method for preparing nanofibrils from both nondegrading and biodegradable polymers for use as tissue engineering scaffolds.
- the present invention relates to delivery systems for the controlled release of bioactive compounds which comprise polymeric fibers and the bioactive compound.
- An object of the present invention is to provide a system for delivery of bioactive compounds comprising a bioactive compound incorporated within or between a polymeric fiber matrix or linear assembly, film coating or braided/woven structure.
- Another object of the present invention is to provide a method for delivering a bioactive compound to a patient for controlled release of the bioactive compound in the patient.
- the bioactive compound is incorporated into a polymeric fiber matrix or linear assembly or a braided or woven structure and implanted into the patient.
- the bioactive compound is incorporated into a polymeric fiber film used to coat implants, tissue engineering scaffolds and other devices such as pumps and pacemakers which are then implanted into the patient.
- the bioactive compound is incorporated into a polymeric fiber film used to wrap organs, tissues or vessels in a patient.
- Another object of the present invention is to provide methods for modulating the rate of release of a bioactive compound from a delivery system for bioactive compounds comprising a bioactive compound incorporated within or between polymeric fibers. These methods include modulating loading of the bioactive compound incorporated with or between polymeric fiber, selecting polymers to produce the polymeric fibers which degrade at varying rates, varying polymeric concentration of the polymeric fibers and varying polymeric fiber diameter.
- Electrospinning is a simple and low cost electrostatic self-assembly method capable of fabricating a large variety of long, meter-length, organic polymer fibers with micron or submicron diameters, in linear, 2-D and 3-D architecture. Electrospinning techniques have been available since the 1930's (U.S. Pat. No. 1,975,504). In the electrospinning process, a high voltage electric field is generated between oppositely charged polymer fluid contained in a glass syringe with a capillary tip and a metallic collection screen. As the voltage is increased, the charged polymer solution is attracted to the screen.
- the charge overcomes the surface tension of the suspended polymer cone formed on the capillary tip of the syringe and a jet of ultrafine fibers is produced.
- the solvent quickly evaporates and the fibers are accumulated randomly on the surface of the collection screen. This results in a nonwoven mesh of nano and micron scale fibers.
- Varying the charge density (applied voltage), polymer solution concentration, solvent used, and the duration of electrospinning can control the fiber diameter and mesh thickness.
- Other electrospinning parameters which may be varied routinely to effect the fiber matrix properties include distance between the needle and collection plate, the angle of syringe with respect to the collection plate, and the applied voltage.
- electrospinning is used to produce polymeric fiber matrices with the capability of releasing bioactive compounds in a controlled manner over a selected period of time.
- the delivery system of the present invention is used to maintain delivery of a steady concentration of bioactive compound.
- the delivery system is used in pulsed delivery of the bioactive compound wherein the compound is released in multiple phases in accordance with either rapid or slow degradation of the polymer fibers or diffusion of the bioactive compound from the polymer fibers.
- the delivery system is used to obtain a delayed release of a bioactive compound.
- the bioactive compound-containing fiber polymer matrix can be coated with a layer of nonwoven polymer fiber matrix with no bioactive compound. In this embodiment, different polymers with different degradation times can be used to obtain the desired time delays.
- the delivery systems of the present invention can be used to deliver a single bioactive compound, more than one Ibioactive compound at the same time, or more than one bioactive compound in sequence.
- a bioactive compound and “the bioactive compound”, are meant to be inclusive of one or more bioactive compounds.
- fiber it is meant to include fibrils ranging in diameter from submicron, i.e. approximately 1 to 100 nanometers (10 ⁇ 9 to 10 ⁇ 7 meters) to micron, i.e. approximately 1-1000 micrometers.
- the bioactive compound is incorporated within the polymeric fibers either by suspension of compound particles or dissolution of the compound in the solvent used to dissolve the polymer prior to electrospinning of the polymeric fibers.
- incorporated within it is meant to include embodiments wherein the bioactive compound is inside the fiber as well as embodiments wherein the bioactive compound is dispersed between the fibers.
- the polymeric fibers comprising the bioactive compound can be arranged as matrices, linear assemblies, or braided or woven structures.
- the fibers which release a bioactive compound can serve as film coatings for devices such as implants, tissue engineering scaffolds, pumps, pacemakers and other composites.
- These fiber assemblies can be spun from any polymer which can be dissolved in a solvent.
- the solvent can be either organic or aqueous depending upon the selected polymer.
- polymers which can be used in production of the polymeric fibers of the present invention include, but are not limited to, nondegradable polymers such as polyethylenes, polyurethanes, and EVA, and biodegradable polymers such as poly(lactic acid-glycolic acid), poly(lactic acid), poly(glycolic acid), poly(glaxanone), poly(orthoesters), poly(pyrolic acid) and poly(phosphazenes).
- bioactive compound is to reside within or inside the polymer fiber, selection of the polymer should be based upon the solubility of the bioactive compound within the polymer solution.
- Water soluble polymers such as polyethylene oxide can be used if the bioactive compound also dissolves in water.
- hydrophobic bioactive compounds which are soluble in organic solvent such as steroids can be dissolved in an organic solvent together with a hydrophobic polymer such as polylactic glycolic acid (PLAGA).
- bioactive compound is to reside between the polymer fibers, dissolution of the bioactive compound in the polymer solution is not required. Instead, the bioactive compound can be suspended in the polymer solution prior to electrospinning of the fibers.
- the bioactive compound-containing fibers can be splayed directly onto devices such as implants, tissue engineering scaffolds, pumps and pacemakers as a film coating.
- devices such as implants, tissue engineering scaffolds, pumps and pacemakers as a film coating.
- preferred bioactive compounds include tissue growth factors and angiogenesis factors.
- the bioactive compound may comprise an anti-clotting factor. The coated device is then implanted into a patient wherein the bioactive compound or compounds are released upon degradation of or by diffusion from, or combinations thereof, the polymeric fiber film.
- a matrix or linear assembly of the bioactive compound-containing fibers is prepared.
- the matrix or linear assembly of bioactive compound-containing fibers can be sandwiched between layers of polymer which contain no bioactive compound to decrease any burst effect and/or to obtain a delayed release.
- the matrix may comprise layers of fibers containing different bioactive compounds.
- the matrix or linear assembly is then implanted into a patient for controlled release of the bioactive compound as the polymeric fibers degrade or as the bioactive compound diffuses from the polymeric fibers.
- the time delay can be controlled by varying the choice of polymer used in the fibers, the concentration of polymer used in the fiber, the diameter of the polymeric fibers, and/or the amount of bioactive compound loaded in the fiber.
- the delivery systems of the present invention may be placed on the wound of a patient to enhance healing via release of the bioactive compound. Delivery systems may also be placed on the surface or wrapped around an organ, tissue or vessel for delivery of the bioactive compound to the organ tissue or vessel.
- a braided, knitted or woven structure of bioactive compound-containing fibers is prepared. These structures are prepared using an extension of the traditional 2-dimensional braiding technology in which fabric is constructed by the intertwining or orthogonal interlacing of yarns to form an integral structure through position displacement.
- a wide range of 3-dimensional structures comprising the bioactive compound-containing fibers can be fabricated in a circular or rectangular loom.
- the structure may comprise only bioactive compound-containing fibers, bioactive compound-containing fibers sandwiched between polymeric fibers which contain no bioactive compound, or a mixtures of fibers containing different bioactive compounds.
- this structure can be implanted into a patient for controlled release of the bioactive compound or compounds as the polymeric fibers degrade or as the bioactive compound diffuses from the polymeric fibers.
- delivery rate of the bioactive compound can be controlled by varying the choice of polymer used in the fibers, the concentration of polymer used in the fiber, the diameter of the polymeric fibers, and/or the amount of bioactive compound loaded in the fiber.
- the present invention also relates to methods for modulating the rate of release of a bioactive compound from a delivery system for bioactive compounds comprising a bioactive compound incorporated within or between polymeric fibers.
- modulate or “modulating”, it is meant that the rate or release of the bioactive compound incorporated within of between the polymeric fibers of the delivery system is increased or decreased.
- Methods for modulating the rate of release include increasing or decreasing loading of the bioactive compound incorporated within or between the polymeric fibers, selecting polymers to produce the polymeric fibers which degrade at varying rates, varying polymeric concentration of the polymeric fibers and/or varying diameter of the polymeric fibers varying one or more of these parameters can be performed routinely by those of skill in the art based upon teachings provided herein.
- FITC-BSA fluorescently labeled bovine serum albumin
- the charge overcomes the surface tension of the deformed polymer drop at the needle tip, producing an ultrafine jet.
- the similarly charged fibers are splayed and during their passage to the screen, the solvent quickly evaporates so that dry fibers accumulate randomly on the screen forming a mesh matrix.
- a 25% (w/v) solution of polylactic glycolic acid was prepared in a 50:50 mixture of dimethylformamide and tetrahydrofuran.
- a mixture of FITC-BSA and BSA in the ratio of 1:5 was added to the solution in order to obtain 2% protein loading.
- a syringe containing 5 ml of the polymer plus bioactive compound mixture was placed at an angle of 45°.
- the syringe was fitted with a 16G needle with the tip of the needle at a distance of 24 cm from the metallic collection screen.
- a piece of nonwoven mat was placed on the metallic screen.
- a voltage of 20 kV was applied between the collection screen and the needle tip which resulted in fibers being sprayed into a nonwoven matrix on the metallic screen. The spraying was complete in about 4 hours.
- phosphate buffered saline was measured. Pre-weighed pieces from different regions of the mat were placed into scintillation vials and 10 ml of phosphate buffered saline were added and the capped vials were placed on a rotary shaker at 37° C. The buffer was exchanged at different points in time in order to mimic infinite sink conditions. The amount of protein released was measured in the form of fluorescence of the FITC-BSA on a spectrophotofluorometer at an excitation wavelength of 495 nm and an emission wavelength of 513 nm.
Abstract
Multifunctional systems for delivery of bioactive compounds incorporated within or between polymeric fibers in a matrix are provided. Also provided are methods of delivering bioactive compounds via implementation, coating and/or wrapping of these systems and methods for modulating the rate of release of bioactive compounds from these delivery systems.
Description
- The present invention relates to delivery systems comprising polymeric fiber matrices, film coatings or braided/woven structures for the controlled release of bioactive compounds. The delivery systems of the present invention may be comprised of either biodegradable or nondegrading polymeric fibers. In one embodiment, these fibers have submicron and/or micron diameters. Bioactive compounds are included in the delivery system either by suspending the compound particles or dissolving the compound in the polymer solution used to produce the fibers.
- A number of polymer matrices for use in the controlled release and/or delivery of bioactive compounds, and for particular drugs, have been described.
- U.S. Pat. No. 3,991,766 describes a medicament repository consisting of a surgical element in the form of tubes, sheets, sponges, gauzes or prosthetic devices of polyglycolic acid having incorporated therein an effective amount of a medicament.
- U.S. Pat. No. 4,655,777 describes a method for producing a biodegradable prothesis or implant by encasing an effective amount of fibers of calcium phosphate or calcium aluminate in a matrix of polymer selected from the group consisting of polyglycolide, poly(DL-lactide), poly(L-lactide), polycaprolactone, polydioxanone, polyesteramides, copolyoxalates, polycarbonates, poly(glutamic-co-leucine) and blends, copolymers and terpolymers thereof to form a composite.
- U.S. Pat. No. 4,818,542 discloses a method for preparing a spherical microporous polymeric network with interconnecting channels having a drug distributed within the channels.
- U.S. Pat. No. 5,128,170 discloses a medical device and methods for manufacturing medical devices with a highly biocompatible surface wherein hydrophillic polymer is bonded onto the surface of the medical device covalently through a nitrogen atom.
- U.S. Pat. No. 5,545,409 discloses a composition and method for controlled release of water-soluble proteins comprising a surface-eroding polymer matrix and water-soluble bioactive growth factors.
- U.S. Pat. No. 5,769,830 discloses synthetic, biocompatible, biodegradable polymer fiber scaffolds for cell growth. Fibers are spaced apart by a distance of about 100 to 300 microns for diffusion and may comprise polyanhydrides, polyorthoesters, polyglycolic acid or polymethacrylate. The scaffolds may be coated withe materials such as agar, agarons, gelatin, gum arabic, basement membrane material, collagen type I, II, III, IV or V, fibronectin, laminin, glycosaminoglycans, and mixtures thereof.
- U.S. Pat. No. 5,898,040 discloses a polymeric article for use in drug delivery systems which comprises a polymeric substrate with a highly uniform microporous polymeric surface layer on at least part of the substrate.
- Encapsulation of a bioactive compound within a polymer matrix has also been described. For example, WO 93/07861 discloses polymer microspheres of 50 to 100 microns comprising a compound contained in a fixed oil within the polymer microsphere. U.S. Pat. No. 5,969,020 discloses a foam precursor comprising a crystalline thermoplastic polymer and solid crystalline additive for use in preparation of drug delivery systems.
- Recently, it has been shown that polymer fibers of nanometer diameter can be electrospun from sulfuric acid into a coagulation bath (Reneker, D. H. and Chun, I. Nanotechnology 1996 7:216). In these studies more than 20 polymers including polyethylene oxide, nylon, polyimide, DNA, polyaramide and polyaniline were electrospun into electrically charged fibers which were then collected in sheets or other useful geometrical forms. Electrospinning techniques have also been applied to the production of high performance filters (Doshi, J. and Reneker, D. H. Journal of Electrostatics 1995 35:151; Gibson et al. AIChE Journal 1999 45:190) and for scaffolds in tissue engineering (Doshi, J. and Reneker, D. H. Journal of Electrostatics 1995 35:151; Ko et al. “The Dynamics of Cell-Fiber Architecture Interaction,” Proceedings, Annual Meeting, Biomaterials Research Society, San Diego, Calif., April 1998; and WO 99/18893). WO 99/18893 describes a method for preparing nanofibrils from both nondegrading and biodegradable polymers for use as tissue engineering scaffolds.
- The present invention relates to delivery systems for the controlled release of bioactive compounds which comprise polymeric fibers and the bioactive compound.
- An object of the present invention is to provide a system for delivery of bioactive compounds comprising a bioactive compound incorporated within or between a polymeric fiber matrix or linear assembly, film coating or braided/woven structure.
- Another object of the present invention is to provide a method for delivering a bioactive compound to a patient for controlled release of the bioactive compound in the patient. In one embodiment of this method of the present invention, the bioactive compound is incorporated into a polymeric fiber matrix or linear assembly or a braided or woven structure and implanted into the patient. In another embodiment, the bioactive compound is incorporated into a polymeric fiber film used to coat implants, tissue engineering scaffolds and other devices such as pumps and pacemakers which are then implanted into the patient. In yet another embodiment, the bioactive compound is incorporated into a polymeric fiber film used to wrap organs, tissues or vessels in a patient.
- Another object of the present invention is to provide methods for modulating the rate of release of a bioactive compound from a delivery system for bioactive compounds comprising a bioactive compound incorporated within or between polymeric fibers. These methods include modulating loading of the bioactive compound incorporated with or between polymeric fiber, selecting polymers to produce the polymeric fibers which degrade at varying rates, varying polymeric concentration of the polymeric fibers and varying polymeric fiber diameter.
- Electrospinning is a simple and low cost electrostatic self-assembly method capable of fabricating a large variety of long, meter-length, organic polymer fibers with micron or submicron diameters, in linear, 2-D and 3-D architecture. Electrospinning techniques have been available since the 1930's (U.S. Pat. No. 1,975,504). In the electrospinning process, a high voltage electric field is generated between oppositely charged polymer fluid contained in a glass syringe with a capillary tip and a metallic collection screen. As the voltage is increased, the charged polymer solution is attracted to the screen. Once the voltage reaches a critical value, the charge overcomes the surface tension of the suspended polymer cone formed on the capillary tip of the syringe and a jet of ultrafine fibers is produced. As the charged fibers are splayed, the solvent quickly evaporates and the fibers are accumulated randomly on the surface of the collection screen. This results in a nonwoven mesh of nano and micron scale fibers. Varying the charge density (applied voltage), polymer solution concentration, solvent used, and the duration of electrospinning can control the fiber diameter and mesh thickness. Other electrospinning parameters which may be varied routinely to effect the fiber matrix properties include distance between the needle and collection plate, the angle of syringe with respect to the collection plate, and the applied voltage.
- In the present invention, electrospinning is used to produce polymeric fiber matrices with the capability of releasing bioactive compounds in a controlled manner over a selected period of time. In one embodiment, the delivery system of the present invention is used to maintain delivery of a steady concentration of bioactive compound. In another embodiment, the delivery system is used in pulsed delivery of the bioactive compound wherein the compound is released in multiple phases in accordance with either rapid or slow degradation of the polymer fibers or diffusion of the bioactive compound from the polymer fibers. In yet another embodiment, the delivery system is used to obtain a delayed release of a bioactive compound. For example, the bioactive compound-containing fiber polymer matrix can be coated with a layer of nonwoven polymer fiber matrix with no bioactive compound. In this embodiment, different polymers with different degradation times can be used to obtain the desired time delays.
- The delivery systems of the present invention can be used to deliver a single bioactive compound, more than one Ibioactive compound at the same time, or more than one bioactive compound in sequence. Thus, as used herein, the phrases “a bioactive compound” and “the bioactive compound”, are meant to be inclusive of one or more bioactive compounds.
- For purposes of the present invention by “fiber” it is meant to include fibrils ranging in diameter from submicron, i.e. approximately 1 to 100 nanometers (10−9 to 10−7 meters) to micron, i.e. approximately 1-1000 micrometers. The bioactive compound is incorporated within the polymeric fibers either by suspension of compound particles or dissolution of the compound in the solvent used to dissolve the polymer prior to electrospinning of the polymeric fibers. For purposes of the present invention, by “incorporated within” it is meant to include embodiments wherein the bioactive compound is inside the fiber as well as embodiments wherein the bioactive compound is dispersed between the fibers. The polymeric fibers comprising the bioactive compound can be arranged as matrices, linear assemblies, or braided or woven structures. In addition, the fibers which release a bioactive compound can serve as film coatings for devices such as implants, tissue engineering scaffolds, pumps, pacemakers and other composites.
- These fiber assemblies can be spun from any polymer which can be dissolved in a solvent. The solvent can be either organic or aqueous depending upon the selected polymer. Examples of polymers which can be used in production of the polymeric fibers of the present invention include, but are not limited to, nondegradable polymers such as polyethylenes, polyurethanes, and EVA, and biodegradable polymers such as poly(lactic acid-glycolic acid), poly(lactic acid), poly(glycolic acid), poly(glaxanone), poly(orthoesters), poly(pyrolic acid) and poly(phosphazenes).
- Examples of bioactive compounds which can be incorporated into the polymeric fibers include any drug for which controlled release in a patient is desired. Some examples include, but are not limited to, steroids, antifungal agents, and anticancer agents. Other bioactive compounds of particular use in the present invention include tissue growth factors, angiogenesis factors, and anti-clotting factors.
- If the bioactive compound is to reside within or inside the polymer fiber, selection of the polymer should be based upon the solubility of the bioactive compound within the polymer solution. Water soluble polymers such as polyethylene oxide can be used if the bioactive compound also dissolves in water. Alternatively, hydrophobic bioactive compounds which are soluble in organic solvent such as steroids can be dissolved in an organic solvent together with a hydrophobic polymer such as polylactic glycolic acid (PLAGA).
- If the bioactive compound is to reside between the polymer fibers, dissolution of the bioactive compound in the polymer solution is not required. Instead, the bioactive compound can be suspended in the polymer solution prior to electrospinning of the fibers.
- In one embodiment of the present invention, the bioactive compound-containing fibers can be splayed directly onto devices such as implants, tissue engineering scaffolds, pumps and pacemakers as a film coating. For implants and tissue engineering scaffolds, examples of preferred bioactive compounds include tissue growth factors and angiogenesis factors. For pumps or pacemakers, the bioactive compound may comprise an anti-clotting factor. The coated device is then implanted into a patient wherein the bioactive compound or compounds are released upon degradation of or by diffusion from, or combinations thereof, the polymeric fiber film.
- In another embodiment, a matrix or linear assembly of the bioactive compound-containing fibers is prepared. In this embodiment, the matrix or linear assembly of bioactive compound-containing fibers can be sandwiched between layers of polymer which contain no bioactive compound to decrease any burst effect and/or to obtain a delayed release. Alternatively, the matrix may comprise layers of fibers containing different bioactive compounds. The matrix or linear assembly is then implanted into a patient for controlled release of the bioactive compound as the polymeric fibers degrade or as the bioactive compound diffuses from the polymeric fibers. The time delay can be controlled by varying the choice of polymer used in the fibers, the concentration of polymer used in the fiber, the diameter of the polymeric fibers, and/or the amount of bioactive compound loaded in the fiber.
- For purposes of the present invention, by “implanting” or “implanted” as used herein, it is meant to be inclusive of placement of the delivery systems of the present invention into a patient to achieve systemic delivery of the bioactive compound, as well as placement of the delivery system into a patient to achieve local delivery. For example, the delivery systems of the present invention may be placed on the wound of a patient to enhance healing via release of the bioactive compound. Delivery systems may also be placed on the surface or wrapped around an organ, tissue or vessel for delivery of the bioactive compound to the organ tissue or vessel.
- In another embodiment of the present invention, a braided, knitted or woven structure of bioactive compound-containing fibers is prepared. These structures are prepared using an extension of the traditional 2-dimensional braiding technology in which fabric is constructed by the intertwining or orthogonal interlacing of yarns to form an integral structure through position displacement. A wide range of 3-dimensional structures comprising the bioactive compound-containing fibers can be fabricated in a circular or rectangular loom. In this embodiment, the structure may comprise only bioactive compound-containing fibers, bioactive compound-containing fibers sandwiched between polymeric fibers which contain no bioactive compound, or a mixtures of fibers containing different bioactive compounds. Like the matrix or linear assembly, this structure can be implanted into a patient for controlled release of the bioactive compound or compounds as the polymeric fibers degrade or as the bioactive compound diffuses from the polymeric fibers. Again, delivery rate of the bioactive compound can be controlled by varying the choice of polymer used in the fibers, the concentration of polymer used in the fiber, the diameter of the polymeric fibers, and/or the amount of bioactive compound loaded in the fiber.
- Accordingly, the present invention also relates to methods for modulating the rate of release of a bioactive compound from a delivery system for bioactive compounds comprising a bioactive compound incorporated within or between polymeric fibers. By “modulate” or “modulating”, it is meant that the rate or release of the bioactive compound incorporated within of between the polymeric fibers of the delivery system is increased or decreased. Methods for modulating the rate of release include increasing or decreasing loading of the bioactive compound incorporated within or between the polymeric fibers, selecting polymers to produce the polymeric fibers which degrade at varying rates, varying polymeric concentration of the polymeric fibers and/or varying diameter of the polymeric fibers varying one or more of these parameters can be performed routinely by those of skill in the art based upon teachings provided herein.
- The ability of systems of the present invention to release a bioactive compound in a controlled manner was demonstrated using polymeric fiber matrices containing fluorescently labeled bovine serum albumin (FITC-BSA) dispersed between the fibers of the matrix. To construct the bioactive compound-loaded matrices, various concentrations of finely ground FITC-BSA were suspended in biodegradable polymer polylactic glycolic acid in 50:50 dimethyl formamide:tetrahydrofuran. Suspensions contained in a glass syringe with a capillary tip were electrospun into approximately 500 nm diameter fibers via an electrostatic based self-assembly process in which a high voltage electric field was generated between the oppositely charged polymer and a metallic collection screen. At a critical voltage the charge overcomes the surface tension of the deformed polymer drop at the needle tip, producing an ultrafine jet. The similarly charged fibers are splayed and during their passage to the screen, the solvent quickly evaporates so that dry fibers accumulate randomly on the screen forming a mesh matrix.
- The material properties of this mesh matrix of bioactive compound-containing fibers were examined via standard electron microscopy and tensile testing. It was found that tensile strength and the release profiles were a function of protein loading.
- In vitro release of the FITC-BSA into an infinite sink of 37° C. phosphate buffered saline was also measured. This sink mimics in vivo conditions. While release in the first 24 hours after initiation was dominant, release to over 120 hours was observed with an increase in release at the point where the fibers started to breakdown.
- The following nonlimiting examples are provided to further illustrate the present invention.
- A 25% (w/v) solution of polylactic glycolic acid was prepared in a 50:50 mixture of dimethylformamide and tetrahydrofuran. A mixture of FITC-BSA and BSA in the ratio of 1:5 was added to the solution in order to obtain 2% protein loading. A syringe containing 5 ml of the polymer plus bioactive compound mixture was placed at an angle of 45°. The syringe was fitted with a 16G needle with the tip of the needle at a distance of 24 cm from the metallic collection screen. A piece of nonwoven mat was placed on the metallic screen. A voltage of 20 kV was applied between the collection screen and the needle tip which resulted in fibers being sprayed into a nonwoven matrix on the metallic screen. The spraying was complete in about 4 hours.
- It was found that with this specific polymer solvent system, polymer concentrations lower than 25% resulted in fibers with beads of polymers. These beads were eliminated when the polymer concentration was increased to 25% or greater. However, as will be understood by the skilled artisan upon reading this disclosure, this concentration will vary for different polymer/solvent systems and different bioactive compounds.
- In vitro release of the FITC-BSA into an infinite sink of 37° C. phosphate buffered saline was measured. Pre-weighed pieces from different regions of the mat were placed into scintillation vials and 10 ml of phosphate buffered saline were added and the capped vials were placed on a rotary shaker at 37° C. The buffer was exchanged at different points in time in order to mimic infinite sink conditions. The amount of protein released was measured in the form of fluorescence of the FITC-BSA on a spectrophotofluorometer at an excitation wavelength of 495 nm and an emission wavelength of 513 nm.
Claims (14)
1. A system for delivery of bioactive compounds comprising a bioactive compound incorporated within or between polymeric fibers.
2. The system of claim 1 which is biodegradable.
3. The system of claim 1 which is nondegradable.
4. The system of claim 1 wherein the fibers are arranged as a matrix or linear assembly, a film coating on a device, or a braided or woven structure.
5. The system of claim 1 wherein particles of the bioactive compound are suspended in a polymer solution prior to electrospinning of the polymeric fibers so that the bioactive compound is incorporated between the polymeric fibers.
6. The system of claim 1 wherein the bioactive compound is dissolved into a polymer solution prior to electrospinning of the polymeric fibers so that the bioactive compound is incorporated within the polymeric fibers.
7. The system of claim 1 comprising more than one bioactive compound incorporated into a single or multiple layers of polymeric fibers for delivery of the bioactive compounds sequentially or in concert.
8. A method for delivering bioactive compounds to a patient comprising incorporating a bioactive compound into a polymeric fiber matrix or linear assembly or a braided or woven structure and implanting the polymer fiber matrix or linear assembly or braided or woven structure into the patient.
9. The method of claim 8 further comprising coating a device with the polymeric fiber matrix or linear assembly or braided or nonwoven structure and implanting the coated device into the patient for delivery of the bioactive compounds.
10. The method of claim 9 wherein the device comprises a tissue engineering device and the bioactive compound enhances cell attachment and growth to the device.
11. The method of claim 8 wherein the polymeric fiber matrix or linear assembly or a braided or woven structure is implanted directly on a wound of the patient to deliver the bioactive compound to the wound of the patient.
12. The method of claim 8 wherein the polymeric fiber matrix or linear assembly or a braided or woven structure is implanted on the surface of an organ, tissue or vessel of the patient to deliver the bioactive compound to the organ, tissue or vessel of the patient.
13. The method of claim 12 wherein the polymeric fiber matrix or linear assembly or a braided or woven structure is wrapped around the surface of an organ, tissue or vessel of the patient.
14. A method for modulating rate of release of a bioactive compound from a delivery system for bioactive compounds comprising a bioactive compound incorporated within or between polymeric fibers, said method comprising modulating loading of the bioactive compound incorporated with or between polymeric fiber, selecting polymers to produce polymeric fibers which degrade at varying rates, varying diameter of the polymeric fibers, or varying polymeric concentration of the polymeric fibers.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/312,189 US20050158362A1 (en) | 2000-06-23 | 2001-06-25 | Polymeric, fiber matrix delivery systems for bioactive compounds |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21403400P | 2000-06-23 | 2000-06-23 | |
PCT/US2001/041133 WO2002000149A1 (en) | 2000-06-23 | 2001-06-25 | Polymeric, fiber matrix delivery systems for bioactive compounds |
US10/312,189 US20050158362A1 (en) | 2000-06-23 | 2001-06-25 | Polymeric, fiber matrix delivery systems for bioactive compounds |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/128,036 Continuation US7016883B2 (en) | 2002-04-23 | 2002-04-23 | Reverse caching for residential end-users to reduce usage of access links to a core communication network |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050158362A1 true US20050158362A1 (en) | 2005-07-21 |
Family
ID=22797516
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/312,189 Abandoned US20050158362A1 (en) | 2000-06-23 | 2001-06-25 | Polymeric, fiber matrix delivery systems for bioactive compounds |
US09/895,674 Expired - Fee Related US6753311B2 (en) | 2000-06-23 | 2001-06-28 | Collagen or collagen-like peptide containing polymeric matrices |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/895,674 Expired - Fee Related US6753311B2 (en) | 2000-06-23 | 2001-06-28 | Collagen or collagen-like peptide containing polymeric matrices |
Country Status (3)
Country | Link |
---|---|
US (2) | US20050158362A1 (en) |
AU (1) | AU2001273632A1 (en) |
WO (1) | WO2002000149A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060200232A1 (en) * | 2005-03-04 | 2006-09-07 | Phaneuf Matthew D | Nanofibrous materials as drug, protein, or genetic release vehicles |
DE102006061539A1 (en) * | 2006-12-27 | 2008-07-03 | Paul Hartmann Ag | Layer of flat material contacting wound, includes fibrous material bonded with particles having core and casing, containing healing substance released in contact with moisture |
US20090192609A1 (en) * | 2008-01-29 | 2009-07-30 | Zimmer, Inc. | Implant device for use in an implant system |
US20100008994A1 (en) * | 2006-05-09 | 2010-01-14 | The University Of Akron | Electrospun structures and methods for forming and using same |
EP2644191A1 (en) * | 2012-03-30 | 2013-10-02 | Universitat Politécnica De Catalunya | Nonwoven membrane as a drug delivery system |
WO2013165604A1 (en) * | 2012-05-02 | 2013-11-07 | Massachusetts Institute Of Technology | Electroprocessing of active pharmaceutical ingredients |
US8771582B2 (en) | 2005-03-04 | 2014-07-08 | BioScurfaces, Inc. | Electrospinning process for making a textile suitable for use as a medical article |
US9205089B2 (en) | 2011-04-29 | 2015-12-08 | Massachusetts Institute Of Technology | Layer processing for pharmaceuticals |
US20160106878A1 (en) * | 2013-05-22 | 2016-04-21 | The Penn State Research Foundation | Wound Dressings and Applications Thereof |
US10213960B2 (en) | 2014-05-20 | 2019-02-26 | Massachusetts Institute Of Technology | Plasticity induced bonding |
US10328032B2 (en) | 2005-03-04 | 2019-06-25 | Biosurfaces, Inc. | Nanofibrous materials as drug, protein, or genetic release vehicles |
JP7389105B2 (en) | 2018-08-03 | 2023-11-29 | セビオテックス,エス.エル. | Beaded nonwoven membranes as drug delivery systems |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020081732A1 (en) | 2000-10-18 | 2002-06-27 | Bowlin Gary L. | Electroprocessing in drug delivery and cell encapsulation |
US6821479B1 (en) * | 2001-06-12 | 2004-11-23 | The University Of Akron | Preservation of biological materials using fiber-forming techniques |
US7105124B2 (en) * | 2001-06-19 | 2006-09-12 | Aaf-Mcquay, Inc. | Method, apparatus and product for manufacturing nanofiber media |
DE10157124A1 (en) * | 2001-11-21 | 2003-05-28 | Lohmann Therapie Syst Lts | Controlled release device useful for e.g. oral or transdermal administration of pharmaceuticals comprises a microfiber including releasable active material |
US20030180268A1 (en) * | 2002-02-05 | 2003-09-25 | Anthony Atala | Tissue engineered construct for supplementing or replacing a damaged organ |
US20040115771A1 (en) * | 2002-09-27 | 2004-06-17 | Thomas Jefferson University | Recombinant collagen-like proteins |
EP3354240A3 (en) * | 2003-04-23 | 2018-08-29 | The University of Akron | Sequestered reactive materials |
FI20045260A (en) * | 2003-11-18 | 2005-05-19 | Teknillinen Korkeakoulu | Process for manufacturing a fiber structure |
US7879440B2 (en) | 2003-11-25 | 2011-02-01 | Asahi Kasei Life & Living Corporation | Matte film |
WO2006044832A2 (en) * | 2004-10-15 | 2006-04-27 | The Cleveland Clinic Foundation | Device for tissue engineering |
US20060154063A1 (en) * | 2004-12-15 | 2006-07-13 | Kazutoshi Fujihara | Nanofiber construct and method of preparing thereof |
US20060204445A1 (en) * | 2005-03-11 | 2006-09-14 | Anthony Atala | Cell scaffold matrices with image contrast agents |
WO2006099332A2 (en) | 2005-03-11 | 2006-09-21 | Wake Forest University Health Sciences | Production of tissue engineered digits and limbs |
US7531503B2 (en) * | 2005-03-11 | 2009-05-12 | Wake Forest University Health Sciences | Cell scaffold matrices with incorporated therapeutic agents |
AU2006223112B2 (en) | 2005-03-11 | 2011-12-01 | Wake Forest University Health Sciences | Production of tissue engineered heart valves |
CA2602029C (en) | 2005-03-11 | 2014-07-15 | Wake Forest University Health Sciences | Tissue engineered blood vessels |
US20060204539A1 (en) | 2005-03-11 | 2006-09-14 | Anthony Atala | Electrospun cell matrices |
US8048446B2 (en) * | 2005-05-10 | 2011-11-01 | Drexel University | Electrospun blends of natural and synthetic polymer fibers as tissue engineering scaffolds |
US7704347B2 (en) * | 2005-05-27 | 2010-04-27 | Prairie Packaging, Inc. | Reinforced plastic foam cup, method of and apparatus for manufacturing same |
US20090075354A1 (en) * | 2005-06-07 | 2009-03-19 | The University Of Akron | Nanofiber structures for supporting biological materials |
JP5253159B2 (en) | 2005-06-24 | 2013-07-31 | デューク・ユニヴァーシティ | Direct drug delivery system based on thermoresponsive biopolymer |
US8921109B2 (en) | 2005-09-19 | 2014-12-30 | Histogenics Corporation | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof |
KR100751547B1 (en) | 2005-11-21 | 2007-08-23 | 재단법인서울대학교산학협력재단 | Scaffold and method of manufacturing scaffold, and electrospinning device of manufacturing scaffold |
WO2007073486A2 (en) | 2005-12-20 | 2007-06-28 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
EP1971290A2 (en) * | 2006-01-12 | 2008-09-24 | Histogenics Corporation | Method for repair and reconstruction of ruptured ligaments or tendons and for treatment of ligament and tendon injuries |
JP5249785B2 (en) * | 2006-01-27 | 2013-07-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Biomimetic scaffold |
US20080220042A1 (en) * | 2006-01-27 | 2008-09-11 | The Regents Of The University Of California | Biomolecule-linked biomimetic scaffolds |
EP2023852A4 (en) * | 2006-06-09 | 2012-06-27 | Univ California | Biomolecule-linked biomimetic scaffolds |
US8546333B2 (en) | 2007-02-01 | 2013-10-01 | Technion Research & Development Foundation Limited | Albumin fibers and fabrics and methods of generating and using same |
US20080260794A1 (en) * | 2007-02-12 | 2008-10-23 | Lauritzen Nels J | Collagen products and methods for producing collagen products |
US9056151B2 (en) * | 2007-02-12 | 2015-06-16 | Warsaw Orthopedic, Inc. | Methods for collagen processing and products using processed collagen |
US20100018641A1 (en) * | 2007-06-08 | 2010-01-28 | Kimberly-Clark Worldwide, Inc. | Methods of Applying Skin Wellness Agents to a Nonwoven Web Through Electrospinning Nanofibers |
US20100070020A1 (en) * | 2008-06-11 | 2010-03-18 | Nanovasc, Inc. | Implantable Medical Device |
US20090018643A1 (en) * | 2007-06-11 | 2009-01-15 | Nanovasc, Inc. | Stents |
US8293531B1 (en) | 2007-08-31 | 2012-10-23 | Clemson University Research Foundation | Three-dimensional ex vivo system |
US7799261B2 (en) * | 2007-11-30 | 2010-09-21 | Cook Incorporated | Needle-to-needle electrospinning |
US8795577B2 (en) | 2007-11-30 | 2014-08-05 | Cook Medical Technologies Llc | Needle-to-needle electrospinning |
US20100249924A1 (en) * | 2009-03-27 | 2010-09-30 | Allergan, Inc. | Bioerodible matrix for tissue involvement |
PL2464370T3 (en) | 2009-08-14 | 2017-08-31 | Phasebio Pharmaceuticals, Inc. | Modified vasoactive intestinal peptides |
US8637109B2 (en) * | 2009-12-03 | 2014-01-28 | Cook Medical Technologies Llc | Manufacturing methods for covering endoluminal prostheses |
US8460691B2 (en) | 2010-04-23 | 2013-06-11 | Warsaw Orthopedic, Inc. | Fenestrated wound repair scaffold |
US8790699B2 (en) | 2010-04-23 | 2014-07-29 | Warsaw Orthpedic, Inc. | Foam-formed collagen strand |
EP2582868B1 (en) | 2010-06-17 | 2018-03-28 | Washington University | Biomedical patches with aligned fibers |
CA2873553C (en) | 2011-06-06 | 2020-01-28 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
US9175427B2 (en) | 2011-11-14 | 2015-11-03 | Cook Medical Technologies Llc | Electrospun patterned stent graft covering |
US20140017263A1 (en) | 2012-06-28 | 2014-01-16 | Clemson University | Delivery Agents for Targeted Treatment of Elastin Degradation |
IN2015DN02299A (en) | 2012-09-21 | 2015-08-21 | Univ Washington | |
US10154918B2 (en) | 2012-12-28 | 2018-12-18 | Cook Medical Technologies Llc | Endoluminal prosthesis with fiber matrix |
CN103599090A (en) * | 2013-07-30 | 2014-02-26 | 江南大学 | Multi-layer drug sustain-release nano fiber membrane and preparation method thereof |
US9795573B2 (en) | 2013-09-24 | 2017-10-24 | Clemson University | Multi-step connective tissue stabilization method and stabilized tissue formed thereby |
US10092679B2 (en) | 2013-10-18 | 2018-10-09 | Wake Forest University Health Sciences | Laminous vascular constructs combining cell sheet engineering and electrospinning technologies |
JP2017527539A (en) * | 2014-08-04 | 2017-09-21 | ホスピタル サン ホアン デ デュウ | System for immediate release of active agent |
US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
KR101810080B1 (en) * | 2015-06-01 | 2017-12-19 | 주식회사 아모라이프사이언스 | Membrane for dental |
US10632228B2 (en) | 2016-05-12 | 2020-04-28 | Acera Surgical, Inc. | Tissue substitute materials and methods for tissue repair |
CN105908363B (en) * | 2016-05-12 | 2018-07-06 | 华南农业大学 | A kind of electrostatic spraying laminated film and preparation method and application |
EP3533458B1 (en) * | 2018-03-02 | 2023-05-03 | UPM-Kymmene Corporation | A medical product comprising a bioactive molecule immobilized to nanofibrillar cellulose, and a method for preparing thereof |
CN114053249B (en) * | 2020-08-10 | 2023-06-02 | 山东百多安医疗器械股份有限公司 | Degradable medicine carrying film capable of treating systemic osteoporosis and preparation process thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4655777A (en) * | 1983-12-19 | 1987-04-07 | Southern Research Institute | Method of producing biodegradable prosthesis and products therefrom |
US5324519A (en) * | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
US5545409A (en) * | 1989-02-22 | 1996-08-13 | Massachusetts Institute Of Technology | Delivery system for controlled release of bioactive factors |
US6753454B1 (en) * | 1999-10-08 | 2004-06-22 | The University Of Akron | Electrospun fibers and an apparatus therefor |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR707191A (en) | 1929-12-07 | 1931-07-03 | Ver Fur Chemische Ind Ag | Process for making artificial threads |
US3991766A (en) | 1973-05-31 | 1976-11-16 | American Cyanamid Company | Controlled release of medicaments using polymers from glycolic acid |
US4818542A (en) | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
US5804178A (en) * | 1986-11-20 | 1998-09-08 | Massachusetts Institute Of Technology | Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue |
US5128170A (en) | 1989-05-11 | 1992-07-07 | Kanegafunchi Kagaku Kogyo Kabushiki Kaisha | Method for manufacturing medical device having a highly biocompatible surface |
US5769830A (en) | 1991-06-28 | 1998-06-23 | Cook Incorporated | Soft tip guiding catheter |
AU7564494A (en) | 1993-08-13 | 1995-03-14 | Smith & Nephew Richards Inc. | Microporous polymeric foams and microtextured surfaces |
AU1075699A (en) * | 1997-10-10 | 1999-05-03 | Allegheny Health, Education And Research Foundation | Hybrid nanofibril matrices for use as tissue engineering devices |
EP1123067A2 (en) * | 1998-10-20 | 2001-08-16 | TEI Biosciences, Inc. | Cardiovascular components for transplantation and methods of making thereof |
-
2001
- 2001-06-25 US US10/312,189 patent/US20050158362A1/en not_active Abandoned
- 2001-06-25 WO PCT/US2001/041133 patent/WO2002000149A1/en active Application Filing
- 2001-06-25 AU AU2001273632A patent/AU2001273632A1/en not_active Abandoned
- 2001-06-28 US US09/895,674 patent/US6753311B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4655777A (en) * | 1983-12-19 | 1987-04-07 | Southern Research Institute | Method of producing biodegradable prosthesis and products therefrom |
US5545409A (en) * | 1989-02-22 | 1996-08-13 | Massachusetts Institute Of Technology | Delivery system for controlled release of bioactive factors |
US5324519A (en) * | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
US6753454B1 (en) * | 1999-10-08 | 2004-06-22 | The University Of Akron | Electrospun fibers and an apparatus therefor |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060200232A1 (en) * | 2005-03-04 | 2006-09-07 | Phaneuf Matthew D | Nanofibrous materials as drug, protein, or genetic release vehicles |
US10441550B2 (en) | 2005-03-04 | 2019-10-15 | Biosurfaces, Inc. | Nanofibrous materials as drug, protein, or genetic release vehicles |
US10328032B2 (en) | 2005-03-04 | 2019-06-25 | Biosurfaces, Inc. | Nanofibrous materials as drug, protein, or genetic release vehicles |
US8771582B2 (en) | 2005-03-04 | 2014-07-08 | BioScurfaces, Inc. | Electrospinning process for making a textile suitable for use as a medical article |
US20100008994A1 (en) * | 2006-05-09 | 2010-01-14 | The University Of Akron | Electrospun structures and methods for forming and using same |
US8574315B2 (en) * | 2006-05-09 | 2013-11-05 | The University Of Akron | Electrospun structures and methods for forming and using same |
DE102006061539A1 (en) * | 2006-12-27 | 2008-07-03 | Paul Hartmann Ag | Layer of flat material contacting wound, includes fibrous material bonded with particles having core and casing, containing healing substance released in contact with moisture |
US20090192609A1 (en) * | 2008-01-29 | 2009-07-30 | Zimmer, Inc. | Implant device for use in an implant system |
US9205089B2 (en) | 2011-04-29 | 2015-12-08 | Massachusetts Institute Of Technology | Layer processing for pharmaceuticals |
US20150072008A1 (en) * | 2012-03-30 | 2015-03-12 | Universitat Politecnica De Catalunya | Nonwoven membrane as a drug delivery system |
CN108992432A (en) * | 2012-03-30 | 2018-12-14 | 加泰罗尼亚理工大学 | Non-woven membrane as drug delivery system |
EP2644191A1 (en) * | 2012-03-30 | 2013-10-02 | Universitat Politécnica De Catalunya | Nonwoven membrane as a drug delivery system |
WO2013144206A1 (en) | 2012-03-30 | 2013-10-03 | Universitat Politecnica De Catalunya | Nonwoven membrane as a drug delivery system |
EP3108881A1 (en) * | 2012-03-30 | 2016-12-28 | Universitat Politècnica De Catalunya | Nonwoven membrane as a drug delivery system |
US9561190B2 (en) * | 2012-03-30 | 2017-02-07 | Universitat Politecnica De Catalunya | Nonwoven membrane as a drug delivery system |
CN104321051B (en) * | 2012-03-30 | 2018-09-18 | 加泰罗尼亚理工大学 | Non-woven membrane as drug delivery system |
CN104321051A (en) * | 2012-03-30 | 2015-01-28 | 加泰罗尼亚理工大学 | Nonwoven membrane as a drug delivery system |
WO2013165604A1 (en) * | 2012-05-02 | 2013-11-07 | Massachusetts Institute Of Technology | Electroprocessing of active pharmaceutical ingredients |
US20160106878A1 (en) * | 2013-05-22 | 2016-04-21 | The Penn State Research Foundation | Wound Dressings and Applications Thereof |
US11173227B2 (en) * | 2013-05-22 | 2021-11-16 | The Penn State Research Foundation | Wound dressings and applications thereof |
US10213960B2 (en) | 2014-05-20 | 2019-02-26 | Massachusetts Institute Of Technology | Plasticity induced bonding |
US10703048B2 (en) | 2014-05-20 | 2020-07-07 | Massachusetts Institute Of Technology | Plasticity induced bonding |
JP7389105B2 (en) | 2018-08-03 | 2023-11-29 | セビオテックス,エス.エル. | Beaded nonwoven membranes as drug delivery systems |
Also Published As
Publication number | Publication date |
---|---|
WO2002000149A1 (en) | 2002-01-03 |
US6753311B2 (en) | 2004-06-22 |
AU2001273632A1 (en) | 2002-01-08 |
US20030021821A1 (en) | 2003-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050158362A1 (en) | Polymeric, fiber matrix delivery systems for bioactive compounds | |
CN104321051B (en) | Non-woven membrane as drug delivery system | |
US7879093B2 (en) | Electrospun apatite/polymer nano-composite scaffolds | |
Pillay et al. | A review of the effect of processing variables on the fabrication of electrospun nanofibers for drug delivery applications | |
Elahi et al. | Core-shell fibers for biomedical applications-a review | |
EP2968669B1 (en) | Ultrafine electrospun fibers of poly-4-hydroxybutyrate and copolymers thereof | |
Kumbar et al. | Recent patents on electrospun biomedical nanostructures: an overview | |
EP1395303B1 (en) | Implantable biodegradable devices for musculoskeletal repair or regeneration | |
Maleki et al. | Drug release behavior of electrospun twisted yarns as implantable medical devices | |
Su et al. | Encapsulation and controlled release of heparin from electrospun poly (l-lactide-co-ε-caprolactone) nanofibers | |
US20190071796A1 (en) | Process and apparatus for making aligned or twisted electrospun fibers and devices | |
US20060154063A1 (en) | Nanofiber construct and method of preparing thereof | |
AU2002231017A1 (en) | Implantable biodegradable devices for musculoskeletal repair or regeneration | |
JP2017507001A (en) | Time-dependent synthetic biological barrier materials | |
Chiu et al. | Electrospun nanofibrous scaffolds for biomedical applications | |
CN111214708B (en) | Composite film carrying biological active factor PLA/PLGA/CS and preparation method thereof | |
CN1874799A (en) | Medical device with electrospun nanofibers | |
Laurencin et al. | Recent patents on electrospun biomedical nanostructures: an overview | |
US11891727B2 (en) | Thermally and dimensionally stabilized electrospun compositions and methods of making same | |
Kataphinan | Electrospinning and potential applications | |
Adpekar et al. | Electrospun nanofibres and their biomedical applications | |
He et al. | Electrospraying and electrospinning for nanobiomaterial fabrication | |
CA2749328A1 (en) | Biomimetic nanofiber web and method and device to manufacture the same | |
US20230002935A1 (en) | Electrospinning collector for the production of three-dimensional electrospun constructs | |
CZ28387U1 (en) | Vessel replacement, especially small-diameter vessel replacement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DREXEL UNIVERSITY, PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WHEATLEY, MARGARET A.;KO, FRANK K.;DHOOT, NIKHIL;AND OTHERS;REEL/FRAME:017530/0535 Effective date: 20050823 |
|
AS | Assignment |
Owner name: DREXEL UNIVERSITY, PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:EL-SHERIF, DALIA;BENJELLOUN, MERIEM;REEL/FRAME:018979/0274;SIGNING DATES FROM 20070220 TO 20070223 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |